PubMed · 1974 · 16 citations · 0 references
MedicineEndocrinologyOncologyBreast OncologyEndocrine OncologyMetastasisBreast Cancer OncologyEndocrine Tumor DiagnosisEndocrine Tumor PrognosisHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBenign Breast TumorsBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyEstrogen Receptor StatusEstrogen ReceptorsHormone Receptor - Positive Breast CancerHormone Receptor Positive Metastatic DiseaseHormone Receptor-positive Disease
Addition or removal of estrogen is an effective method of palliation for about 1/3 of patients with disseminated cancer of the breast. Estrogen-responsive tissues have in their cytoplasm specific binding proteins termed estrogen receptors which have an affinity for estradiol. In 193 patients tumors were assayed for estrogen receptors (positive results defined as binding index values over 12%) and then estrogen response classified at 1 month by clinicians who had no knowledge of the index results. 30 of the patients had nonmalignant disease of the breast 84 had primary carcinoma and 79 had metastases. Only 4 of the benign tumors were estrogen receptor positive while about 1/2 of the others were positive. Those with metastases in the liver were all estrogen receptor positive. Of those with multiple metastases elsewhere 25% had cell populations of both positive and negative types. Of 40 patients who had endocrine ablation 20 had receptor positive patterns 16 negative and 4 mixed. Of the receptor positive group 10 had complete remission 6 showed partial response 1 unchanged and 3 progression. Liver metastases were present in the 3 not responding. Of the negative patients 13 underwent both oophorectomy and adrenalectomy; 8 did not respond 4 had very short partial response 1 had complete remission of over 6 months. Most of the patients with extrogen receptor negative tumors died within 6 months after endocrine ablation even when treated by chemotherapy. The responders lived more than a year. The significance of estrogen receptors in the patients with benign breast tumors is not known. Reports from 3 other investigators on 57 estrogen receptor positive patients showed that 46 had remissions while only 4 of 79 estrogen receptor negative patients were benefitted by endocrine therapy. To avoid missing the presence of both types of cells the presence of estrogen receptors should be evaluated in more than 1 tumor site from each patient. The presence of estrogen receptors in carcinomas of the breast is the most valid criterion for predicting patient response to hormonal therapy.